Updated pfizer Shot's Real-World power under review
NCT ID NCT06703190
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aimed to measure how well the 2024-2025 Pfizer COVID-19 vaccine prevents symptomatic infection in people visiting CVS MinuteClinics. Researchers planned to compare vaccinated and unvaccinated patients across age groups and variant periods. However, the study was terminated after enrolling only one person, so no reliable conclusions can be drawn.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Pfizer-BioNTech BNT162b2 COVID-19 vaccine (2024-2025 formulation)
- What this could lead to
- If successful, this study could confirm how well the updated vaccine works against current variants and how long protection lasts.
- What could go wrong
- The study was terminated with only 1 participant, so results are not meaningful. It cannot provide reliable estimates of vaccine effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COVID-19 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Pfizer
New York, New York, 10001, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Five years on: how does long COVID evolve?
- Can a targeted pill tame severe COVID-19?
- Can an organic compound tame COVID-19 in High-Risk patients?
- Could exercise retrain the heart in long COVID?
- Can a new drug shield lungs from COVID-19's worst damage?
- Can paxlovid hold the line against severe COVID-19 outside the lab?